Julia Talsma
Pirfenidone reduces disease progression of IPF
Pirfenidone reduces disease progression of IPF
Pirfenidone (Esbriet), an oral antifibrotic therapy, was able to reduce progression of idiopathic pulmonary fibrosis (IPF) and reduce the risk of mortality, according to phase 3 trial results presented at the American Thoracic Society International Conference in San Diego.
Statin therapy: How safe is it?
The National Lipid Association just released a report addressing six safety issues related to statin therapy, including the effects of statins on cognition, diabetes risk, liver function, muscle symptoms, interactions with other drugs, and statin intolerance. The report, published in the Journal of Clinical Lipidology, is an update to a consensus report published by the organization in 2006.
After MI higher dietary fiber intake helps reduce mortality risk
Higher dietary fiber intake among myocardial infarction (MI) survivors lowers the risk of subsequent all cause and cardiovascular mortality, according to a prospective study published April 29 in BMJ.
Post-discharge pharmacist follow-up as important as pre-discharge med review
Pharmacists who contacted high-risk patients within 72 hours of discharge from Massachusetts General Hospital, Boston, found more than half of the patients had medication-related issues. In a different group of high-risk patients who had received inpatient interventions, 35% of patients were found to have issues after a pharmacist reviewed their medications just prior to discharge, according to Laura Carr, PharmD.
Pharmacists manage stroke recovery more effective than nurses
Pharmacist-led care with prescribing authority substantially improved risk factors at 6 months among stroke survivors than nurse case managers who monitored patients and provided feedback to their primary care physicians, according to a report published in the Canadian Medical Association’s journal, CMAJ.
FDA warns of possible neurologic problems after epidural corticosteroid injections
FDA is requiring that drug labels for injectable corticosteroids used to treat neck and back pain must be updated to include a warning of rare but serious adverse events, including vision loss, stroke, paralysis, and death, according to a recent FDA drug safety communication.
FDA approves once-weekly GLP-1 injectable for type 2 diabetes
FDA approved albiglutide (Tanzeum, GlaxoSmithKline), a once-weekly subcutaneous injectable for the treatment of adults with type 2 diabetes. It helps to improve glycemic control, along with diet and exercise.
Increased risk of psychiatric diagnoses seen following ICU admission
Critically ill patients requiring mechanical ventilation in an intensive care unit (ICU) may be at increased risk of a new psychiatric illness and medication use following hospital release, according to a report published March 19 in JAMA.
Generic Talconex now available
Sandoz this week introduced its calcipotriene and betamethasone dipropionate ointment in the United States. It will be the first generic version of Leo Pharma’s Taclonex ointment in the market.
FDA approves OTC Nexium
FDA has approved non-prescription esomeprazole 20mg (Nexium 24HR, Pfizer).

Poll